ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -2 مورد

Long-term prophylaxis to prevent angioedema in adults and pediatric patients with hereditary angioedema (HAE)

Long-term prophylaxis to prevent angioedema in adults and pediatric patients with hereditary angioedema (HAE)
Prophylactic therapy Advantages Disadvantages
C1 inhibitor concentrate – Intravenous
  • Well tolerated
  • Widely available
  • Approved for children aged 6 years and older
  • Requires reliable venous access (but indwelling ports are not recommended)
  • Expensive
C1 inhibitor concentrate – Subcutaneous
  • Convenient – Subcutaneous injection every 3 to 4 days
  • Approved for children aged 6 years and older in the United States
  • Transient injection-site reactions
  • Not approved for use in children younger than 12 years of age in the European Union
  • Expensive
Lanadelumab
  • Convenient – Subcutaneous injection every 2 to 4 weeks
  • Approved for children aged 2 years and older in Europe and the United States
  • Transient injection-site reactions
  • Expensive
Berotralstat
  • Convenient – Once-daily oral administration
  • Not approved for use in children younger than 12 years of age
  • Expensive
Androgens
  • Oral administration
  • Inexpensive
  • Side effects are prohibitive in some patients (hypercholesterolemia, liver enzyme abnormalities, virilization, hypertension, mood effects, weight gain, others)
  • Avoid in prepubertal children (premature closure of growth plate) and in pregnancy (virilization of female fetus)
  • Avoid in patients with liver disease or nephrotic syndrome
Antifibrinolytics – Tranexamic acid (preferred) or epsilon aminocaproic acid
  • Oral administration
  • Safe in children
  • Well tolerated by most patients
  • Inexpensive
  • Less effective than other therapies
  • Avoid in patients with history of thrombosis or thromboembolic disease or risk factor for thrombosis
Treatment for breakthrough symptoms (required in combination with any of the options above)
C1 inhibitor concentrate
  • As above
  • As above
Icatibant
  • Subcutaneous injection
  • Approved for self-administration at home
  • Transient injection-site reactions
Ecallantide
  • Subcutaneous injection
  • Should be given under medical supervision due to possible hypersensitivity reactions, usually within 1 hour
  • Only available in the United States
Plasma – Solvent/detergent-treated or fresh frozen
  • Widely available
  • Inexpensive
  • Efficacy not as well established as other therapies
  • Theoretical risk of transmission of bloodborne agents
  • Requires visit to hospital or clinic for administration
BCRP: breast cancer resistance protein; P-gp: P-glycoprotein.
Graphic 83115 Version 23.0